Icosapent ethyl for the treatment of hypertriglyceridemia.

about

Icosapent ethyl for the treatment of severe hypertriglyceridemia.Fatty Acid Ethyl Esters Are Less Toxic Than Their Parent Fatty Acids Generated during Acute Pancreatitis

P2860

Q27686834-0E4B408F-73DB-4AD3-8475-927D266A5F07 Q39905803-5603820D-8A9A-4C72-9590-F47990B928AB

P2860

Icosapent ethyl for the treatment of hypertriglyceridemia.

Item

http://www.wikidata.org/entity/Q38108834

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Icosapent ethyl for the treatment of hypertriglyceridemia.

@en

type

Item

label

Icosapent ethyl for the treatment of hypertriglyceridemia.

@en

prefLabel

Icosapent ethyl for the treatment of hypertriglyceridemia.

@en

P1476

Icosapent ethyl for the treatment of hypertriglyceridemia.

@en

P2093

Christie M Ballantyne

http://www.w3.org/2001/XMLSchema#string

Paresh N Soni

http://www.w3.org/2001/XMLSchema#string

Rene A Braeckman

http://www.w3.org/2001/XMLSchema#string

P2860

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

Safety considerations with omega-3 fatty acid therapy

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Effects of combination lipid therapy in type 2 diabetes mellitus.

Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

P304

1409-1416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.798645

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23701295

http://www.w3.org/2001/XMLSchema#string

P921

icosapent ethyl

Icosapent ethyl for the treatment of hypertriglyceridemia.

about

P2860

P2860

Icosapent ethyl for the treatment of hypertriglyceridemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921